NewAmsterdam Pharma Company NAMS Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's net income?
- NewAmsterdam Pharma Company (NAMS) reported net income of -$48.44M in Q1 2026.
- How has NewAmsterdam Pharma Company's net income changed year-over-year?
- NewAmsterdam Pharma Company's net income decreased by 22.6% year-over-year, from -$39.53M to -$48.44M.
- What is the long-term trend for NewAmsterdam Pharma Company's net income?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's net income has grown at a 48.6% compound annual growth rate (CAGR), from -$41.79M to -$203.82M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.